[EN] 2-SUBSTITUTED BENZOIC ACID DERIVATIVES AS HM74A RECEPTOR AGONISTS [FR] DERIVES D'ACIDE BENZOIQUE 2-SUBSTITUE EN TANT QU'AGONISTE DU RECEPTEUR HM74A
Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel crytolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).
Methods for use of cryptolepine analogs with hypoglycemic activity
申请人:Shaman Pharmaceuticals, Inc.
公开号:US05925647A1
公开(公告)日:1999-07-20
Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel cryptolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).
2-SUBSTITUTED BENZOIC ACID DERIVATIVES AS HM74A RECEPTOR AGONISTS
申请人:SMITHKLINE BEECHAM CORPORATION
公开号:EP1670749A1
公开(公告)日:2006-06-21
US5741926A
申请人:——
公开号:US5741926A
公开(公告)日:1998-04-21
[EN] CRYPTOLEPINE ANALOGS WITH HYPOGLYCEMIC ACTIVITY<br/>[FR] ANALOGUES DE CRYPTOLEPINE A ACTIVITE HYPOGLYCEMIQUE
申请人:SHAMAN PHARMACEUTICALS, INC.
公开号:WO1996010015A1
公开(公告)日:1996-04-04
(EN) Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel cryptolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).(FR) Nouveaux analogues de cryptolépine utiles comme agents hypoglycémiques, méthodes d'utilisation de ces analogues comme agents hypoglycémiques, par exemple, pour le traitement du diabète, et méthodes de synthèse de ces analogues. En tant qu'agents hypoglycémiques, ces nouveaux analogues de cryptolépine se révèlent utiles pour le traitement du diabète sucré insulino-dépendant (IDDM ou Type I) et du diabète sucré non insulino-dépendant (NIDDM OU Type II).